pipeline-prospector-insert-v1
X

Find Ophthalmology Drugs in Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APX3330

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ocuphire Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 22, 2020

            Details:

            Under the terms and conditions of the deal, Ocuphire earns an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRO-1

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2020

            Details:

            The Phase 2 clinical trial is a multicenter, randomized, double-masked, vehicle-controlled clinical trial that will evaluate the safety and efficacy of NRO-1 in patients with dry eye disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avacincaptad Pegol

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            This 2nd pivotal trial will be an international, sham controlled clinical trial enrolling 400 patients to be randomized to receive monthly administration of Zimura 2 mg or sham.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TP-03

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Vivo Capital

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 08, 2020

            Details:

            The financing will enable Tarsus Pharma's Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline development.